S
Stefan C. Grant
Researcher at Wake Forest University
Publications - 39
Citations - 1307
Stefan C. Grant is an academic researcher from Wake Forest University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 17, co-authored 36 publications receiving 1083 citations. Previous affiliations of Stefan C. Grant include Cornell University & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Phase III Study of Adjuvant Vaccination With Bec2/Bacille Calmette-Guerin in Responding Patients With Limited-Disease Small-Cell Lung Cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)
Giuseppe Giaccone,C. Debruyne,Enriqueta Felip,Paul B. Chapman,Stefan C. Grant,Michael Millward,Luc Thiberville,G. D'Addario,Corneel Coens,Lisa S. Rome,Petr Zatloukal,Oriol Masso,Catherine Legrand +12 more
TL;DR: Vaccination with Bec2/BCG has no impact on outcome of patients with limited-disease small-cell lung cancer responding to combined-modality treatment and vaccination strategies in SCLC may still be warranted using vaccines that produce a better immunologic response.
Journal Article
Long Survival of Patients with Small Cell Lung Cancer after Adjuvant Treatment with the Anti-Idiotypic Antibody BEC2 Plus Bacillus Calmette-Guérin
TL;DR: Immunization of patients with SCLC after standard therapy using BEC2 plus BCG can induce anti-GD3 antibodies and is safe, and the survival and relapse-free survival in this group of patients are substantially better than those observed in a prior group of similar patients.
Journal Article
Immunogenicity of a Fucosyl-GM1-Keyhole Limpet Hemocyanin Conjugate Vaccine in Patients with Small Cell Lung Cancer
Maura N. Dickler,Govindaswami Ragupathi,Nancy X. Liu,Cristina Musselli,Damian J. Martino,Vincent A. Miller,Mark G. Kris,Fred-Thomas Brezicka,Philip O. Livingston,Stefan C. Grant +9 more
TL;DR: The Fuc-GM1-KLH + QS-21 vaccine is safe and immunogenic in patients with SCLC, and all patients demonstrated a serological response, with induction of both IgM and IgG antibodies against Fuc -GM1, despite prior treatment with chemotherapy with or without radiation.
Journal ArticleDOI
Phase I study of green tea extract in patients with advanced lung cancer
TL;DR: This study suggests that while relatively nontoxic at a dose of 3 g/m2 per day, GTE likely has limited activity as a cytotoxic agent, and further study of GTE as a single-agent in established malignancies may not be warranted.
Journal ArticleDOI
Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways
Anandi Sawant,Cara C. Schafer,Tong Huan Jin,Jaroslaw W. Zmijewski,Hubert M. Tse,Justin C. Roth,Zhihuan Sun,Gene P. Siegal,Victor J. Thannickal,Stefan C. Grant,Selvarangan Ponnazhagan,Jessy S. Deshane +11 more
TL;DR: This approach offers a new paradigm to inhibit immunosuppression by direct targeting of MDSC function, to generate effector and persistent memory cells for tumor eradication, and to prevent lung cancer relapse.